Qnovia set to trial smoking cessation inhaler in the US
The company has received clearance from the US FDA to start an open-label Phase I trial for RespiRx nicotine inhaler in smokers.
The company has received clearance from the US FDA to start an open-label Phase I trial for RespiRx nicotine inhaler in smokers.
The primary endpoint results from the trial are expected by the end of the year and will be used to support an FDA approval for the OCT B-Series device.
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
Microbot shifts pivotal trial up a gear with completion expected ahead of schedule
Mendaera wins $73m to advance handheld AI robotics system
GE HealthCare’s Flyrcado PET radiotracer secures FDA approval
Mediwhale secures $12m for AI-powered retina scan